Clinical trials
Phase 1 Recurrence trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Active, not recruiting | 12 |
| Terminated | 10 |
| Recruiting | 6 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 7 |
| University Health Network, Toronto | 7 |
| National Cancer Institute (NCI) | 5 |
| AbbVie | 3 |
| Therapeutic Advances in Childhood Leukemia Consortium | 3 |
| Amgen | 2 |
| Treeline Biosciences, Inc. | 2 |
| AHS Cancer Control Alberta | 1 |
| Arvinas Inc. | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 57 |
| Leukemia, Myeloid, Acute | 14 |
| Multiple Myeloma | 12 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 |
| Leukemia | 10 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Lymphoma | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Burkitt Lymphoma | 6 |
| Dendritic Cell Sarcoma, Interdigitating | 6 |
Trials
Showing 1 to 25 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.